(2S,4R)-1-tert-butyl 2-ethyl 4-hydroxypyrrolidine-1,2-dicarboxylate | 440678-63-7

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: (2S,4R)-1-tert-butyl 2-ethyl 4-hydroxypyrrolidine-1,2-dicarboxylate
• 英文别名: ethyl (2S,4S)-N-tert-butyloxycarbonyl-4-hydroxyprolinate；(2S,4S)-4-Hydroxy-pyrrolidine-1,2-dicarboxylic Acid 1-tert-butyl Ester 2-ethyl Ester；(2S,4S)-4-hydroxypyrrolidine-1,2-dicarboxylic acid 1-tert-butyl ester 2-ethyl ester；1-tert-butyl 2-ethyl (2S,4S)-4-hydroxypyrrolidine-1,2-dicarboxylate；(2S,4S)-1-tert-Butyl 2-ethyl 4-hydroxypyrrolidine-1,2-dicarboxylate；1-O-tert-butyl 2-O-ethyl (2S,4S)-4-hydroxypyrrolidine-1,2-dicarboxylate
• CAS: 440678-63-7
• 化学式: C₁₂H₂₁NO₅
• 分子量: 259.302
• InChiKey: MNMDZSAWTQOEHX-IUCAKERBSA-N

物化性质

• 沸点：
  350.2±42.0 °C(Predicted)
• 密度：
  1.189±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0.9
• 重原子数：
  18
• 可旋转键数：
  5
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.83
• 拓扑面积：
  76.1
• 氢给体数：
  1
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  (2S,4R)-1-tert-butyl 2-ethyl 4-hydroxypyrrolidine-1,2-dicarboxylate 在 lithium hydroxide 、 18-冠醚-6 、 sodium hydride 作用下， 以 四氢呋喃 、 甲醇 、 水 为溶剂， 反应 34.0h， 生成 顺式-1-N-BOC-4-甲氧基-L-脯氨酸
  参考文献：
  名称：

  The Impact of Pyrrolidine Hydroxylation on the Conformation of Proline-Containing Peptides

  摘要：

  [GRAPHICS]A series of eight dipeptides of the general formula Ac-Phe-Pro*-NHMe was synthesized and the thermodynamics of the cis --> trans isomerization about the central amide bond were studied by NMR. Pro* represents the following prolines: L-proline (Pro), L-trans-4-hydroxyproline (Hyp), L-cis-4-hydroxyproline (hyp), L-cis-4-methoxyproline (hyp[OMe]), L-trans-3-hydroxyproline (3-Hyp), L-cis-3-hydroxyproline (3-hyp), L-2,3-trans-3,4-cis-3,4-dihydroxyproline (DHP), and L-2,3-cis-3,4-trans3,4-dihydroxyproline (dhp). The conformation of the pyrrolidine ring in each case is discussed in light of previous structural studies, analysis of potential stereoelectronic effects, and NMR data. Hydroxy substituents at C-4 have a greater impact on cis --> trans isomerization than analogous substituents at C-3 as a result of the intervening bond distances and bridging groups. The position of the equilibrium and its dependence on temperature are a reflection of both enthalpic and entropic factors, the latter being complicated in this study by an Ar-Pro interaction in the cis conformation. The substituents on the pyrrolidine ring determine the conformation of the five-membered ring, which in turn influences the strength of the Ar-Pro interaction, backbone dihedral angles, and the relative energy of the cis and trans species. The ultimate position of the equilibrium depends on a complex blend of steric, electronic, and conformational factors.

  DOI：

  10.1021/jo0490043
• 作为产物：
  描述：

  L-羟基脯氨酸 在 甲酸 、 碳酸氢钠 、 二环己胺 、 三苯基膦 、 偶氮二甲酸二乙酯 作用下， 以 四氢呋喃 、 1,4-二氧六环 、 水 、 乙酸乙酯 、 N,N-二甲基甲酰胺 为溶剂， 反应 6.0h， 生成 (2S,4R)-1-tert-butyl 2-ethyl 4-hydroxypyrrolidine-1,2-dicarboxylate
  参考文献：
  名称：

  主链含有叔胺的新型吡咯烷基肽核酸的合成及其细胞内化

  摘要：

  合成了主链中含有叔胺的吡咯烷肽核酸的新型胸腺嘧啶单体（吡咯烷氨基肽核酸= PAPNA）。混合油...

  DOI：

  10.1246/cl.2006.300

文献信息

• A New Synthetic Method for the Preparation of<i>α</i>,<i>β</i>-Didehydroamino Acid Derivatives by Means of a Wittig-Type Reaction. Syntheses of (2<i>S</i>, 4<i>S</i>)- and (2<i>R</i>, 4<i>R</i>)-4-Hydroxyprolines
  作者：Rumi Kimura、Tanemasa Nagano、Hideki Kinoshita

  DOI：10.1246/bcsj.75.2517

  日期：2002.11

  acid derivatives with high (Z)-selectivity in good yields. Moreover, ethyl (4S)- and (4R)-2-(N-Boc-amino)-4,5-isopropylidenedioxy-2-pentenoates prepared by the present method were converted to (2S, 4S)- and (2R, 4R)-4-hydroxyprolines, respectively.

  在三丁基膦和碱的存在下，N-Boc-和NZ-α-甲苯磺酰基甘氨酸乙酯与各种醛反应，以良好的产率提供相应的α,β-二脱氢氨基酸衍生物，具有高（Z）选择性。此外，通过本方法制备的(4S)-和(4R)-2-(N-Boc-氨基)-4,5-异亚丙基二氧基-2-戊烯酸乙酯转化为(2S, 4S)-和(2R, 4R) )-4-羟脯氨酸，分别。
• PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF DIABETES
  申请人：Ajinomoto Co., Inc.

  公开号：US20160046592A1

  公开（公告）日：2016-02-18

  An object is to provide a novel compound which has a glycogen synthase activation ability, but activates a receptor PPAR to a low degree and is highly safe. Provided is a compound represented by the following general formula (I) or a pharmaceutically acceptable salt thereof: wherein Ar 1 represents any one of the following rings (II) and (III): wherein R 2 represents an alkyl group, and R 3 represents a hydrogen atom or an alkyl group, and R 1 represents any one of the following substituents (IV) and (V):

  提供一种新型化合物，具有糖原合成酶激活能力，但对PPAR受体的激活程度较低且具有高度安全性。提供的化合物由以下一般式(I)或其药学上可接受的盐表示：其中Ar1代表以下环之一(II)和(III)：其中R2代表烷基基团，R3代表氢原子或烷基基团，R1代表以下取代基之一(IV)和(V)：
• NOVEL PROLINE DERIVATIVES
  申请人：Sánchez Rubén Alvarez

  公开号：US20100267722A1

  公开（公告）日：2010-10-21

  The invention relates to a compound of formula (I) wherein A, R 1 -R 6 are as defined in the description and in the claims. The compound of formula (I) can be used as a medicament.

  这项发明涉及一种化合物，其化学式为（I），其中A，R1-R6如描述和权利要求中所定义。化合物的化学式（I）可用作药物。
• Structure-based design, synthesis, X-ray studies, and biological evaluation of novel HIV-1 protease inhibitors containing isophthalamide-derived P2-ligands
  作者：Arun K. Ghosh、Jun Takayama、Luke A. Kassekert、Jean-Rene Ella-Menye、Sofiya Yashchuk、Johnson Agniswamy、Yuan-Fang Wang、Manabu Aoki、Masayuki Amano、Irene T. Weber、Hiroaki Mitsuya

  DOI：10.1016/j.bmcl.2015.05.052

  日期：2015.11

  synthesis and biological evaluation of a series of novel HIV-1 protease inhibitors bearing isophthalamide derivatives as the P2–P3 ligands. We have investigated a range of acyclic and heterocyclic amides as the extended P2–P3 ligands. These inhibitors displayed good to excellent HIV-1 protease inhibitory activity. Also, a number of inhibitors showed very good antiviral activity in MT cells. Compound

  我们描述了一系列以间苯二甲酰胺衍生物作为P2-P3配体的新型HIV-1蛋白酶抑制剂的设计，合成和生物学评估。我们研究了一系列无环和杂环酰胺作为扩展的P2-P3配体。这些抑制剂表现出良好至优异的HIV-1蛋白酶抑制活性。同样，许多抑制剂在MT细胞中显示出非常好的抗病毒活性。化合物5n显示的酶K i为0.17 nM，抗病毒IC 50为14 nM。以1.11的分辨率测定了与HIV-1蛋白酶结合的抑制剂5o的X射线晶体结构。这种结构揭示了重要的分子洞察力，了解活性位点中的抑制剂与HIV-1蛋白酶的相互作用。
• Proline derivatives
  申请人：Hoffman-La Roche Inc.

  公开号：US08163793B2

  公开（公告）日：2012-04-24

  The invention relates to a compound of formula (I) wherein A, R1-R6 are as defined in the description and in the claims. The compound of formula (I) can be used as a medicament.

  本发明涉及一种式为(I)的化合物，其中A，R1-R6在说明书和权利要求书中定义。式(I)化合物可用作药物。